By Stephen Nakrosis 
 

Sellas Life Sciences Group Inc. shares rose premarket Wednesday, after the company said it saw promising updated clinical data and initial immunobiological data from an ovarian cancer treatment.

The biopharmaceutical company said updated data from its ongoing Phase 1/2 study of Galinpepimut-S combined with Keytruda to treat WT1+ advanced ovarian cancer showed all patients alive and 45.5% continuing investigational therapy as of the latest follow-up.

At 9:14 a.m. ET, Sellas shares were trading 14.8% higher at $15.01. Volume at the time topped 443,000 shares.

The stock closed Tuesday down 4.8% at $13.07 a share.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

June 30, 2021 09:37 ET (13:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Merck Charts.